Top Page
Alligator Bioscience AB
(ATORX)
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Alligator Bioscience AB Business Overview & Revenue Model
Alligator Bioscience AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -110.03M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -121.98M | -165.47M | -237.61M | -180.99M | -130.39M |
| Net Income | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | |||||
| Total Assets | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 60.41M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | |||||
| Free Cash Flow | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Alligator Bioscience AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr169.76M | -3.34 | -52.45% | ― | 2.56% | 52.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr35.87M | -0.65 | -294.38% | ― | 186.74% | 73.17% | |
43 Neutral | kr37.83M | -1.33 | -166.94% | ― | ― | -19.35% | |
42 Neutral | kr104.32M | -2.22 | -20.85% | ― | -67.00% | 13.62% | |
40 Underperform | kr123.63M | -1.93 | -1291.15% | ― | ― | 28.54% | |
38 Underperform | kr99.15M | -0.17 | ― | ― | 52.38% | 74.36% |
Alligator Bioscience AB Corporate Events
Alligator Bioscience reported its 2025 year-end results highlighting a rights issue that raised approximately SEK 91 million before costs to bolster liquidity and support further development of lead cancer drug candidate mitazalimab. The financing, complemented by bridge loans and potential future warrant proceeds, aims to secure the company’s transition of mitazalimab into its next development phase, despite continued operating losses and modest net sales.
The company advanced its scientific and strategic position through new peer-reviewed publications and congress presentations validating mitazalimab and ATOR-4066, and by securing a U.S. patent for ATOR-4066 to reinforce intellectual property and long-term asset value. Partner Shanghai Henlius progressed the HLX22 program into Phase 2/3 breast cancer trials in China, preserving a potential future revenue stream for Alligator via milestones and royalties and underscoring the broader commercial optionality of its portfolio.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.18 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience will publish its full-year 2025 report on 12 February 2026 and on the same day host an English-language webinar and conference call for investors, analysts and media, led by CEO Søren Bregenholt and CFO Johan Giléus. The event, which requires advance registration and will include a Q&A session, underlines the company’s effort to engage the capital markets around its financial performance and development progress, with the full report to be made available on its website upon release.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.18 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience AB has increased its total number of outstanding shares and votes to 534,516,986 ordinary shares as of 30 January 2026, following a rights issue of units approved in late 2025 and a subsequent directed issue of units to guarantors. The expanded share base reflects the company’s ongoing capital-raising efforts to support its strategic and operational needs, potentially affecting existing shareholders through dilution while strengthening Alligator Bioscience’s financial position and flexibility within the competitive biotech sector.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.18 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience will present new clinical data from its Phase 1b/2 OPTIMIZE-1 study of the CD40 agonist mitazalimab in combination with standard mFOLFIRINOX chemotherapy in previously untreated metastatic pancreatic ductal adenocarcinoma at the ASCO Gastrointestinal Cancers Symposium 2026 in San Francisco. The final efficacy analyses further characterize the clinical benefit of the combination and support Alligator’s preparations for pivotal development of mitazalimab, potentially strengthening the drug’s profile in a highly challenging cancer indication and reinforcing the company’s positioning in CD40-based immunotherapy as it engages key opinion leaders and advances toward Phase 3.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience’s board has executed a directed issue of 18,585,000 units to guarantors of its recent rights issue, with each unit consisting of two ordinary shares and one warrant, at a subscription price of SEK 0.40 per unit (SEK 0.20 per share), matching the rights issue terms. Eleven guarantors opted to take their guarantee compensation in newly issued units worth approximately SEK 7.4 million, while the remaining guarantors will receive around SEK 3.8 million in cash, and the board has also approved a directed issue of 28,132,473 warrants to Fenja Capital, collectively strengthening the company’s capital structure and aligning key investors through equity-linked instruments, albeit at the cost of further dilution for existing shareholders.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
Alligator Bioscience has completed a rights issue of units that was subscribed to about 64.8 percent, with approximately 61.2 percent taken up by existing shareholders through unit rights and 3.6 percent subscribed without rights, while guarantee commitments will cover around 9.1 percent of the issue. The transaction will initially raise roughly SEK 91 million before costs and loan repayments, significantly increasing the company’s share count and resulting in an estimated 91.2 percent dilution for existing shareholders, with the potential for a further dilution of about 31.3 percent if all associated TO 14 warrants are exercised in March 2026, which could bring in up to SEK 57 million more and materially extend the company’s funding but at a substantial ownership dilution.
Alligator Bioscience has reported the preliminary outcome of its recently completed rights issue of units, indicating a subscription level of approximately 64.8 percent, of which 61.2 percent came through the exercise of unit rights and 3.6 percent without rights. As a result, guarantee commitments will be utilized for about 9.1 percent of the offering, and the company expects to raise roughly SEK 91 million before issue costs and debt repayments, including bridge loans and part of an outstanding loan to Fenja Capital II A/S. The rights issue, which comprised up to 306.7 million units—each consisting of two ordinary shares and one warrant—closed on 18 December 2025, with the final outcome scheduled to be announced on 22 December 2025, providing Alligator with important capital to support its ongoing operations and clinical pipeline.
Alligator Bioscience has commented on Shanghai Henlius Biotech’s recent regulatory approval in China to begin Phase 2/3 trials of HLX22, a monoclonal antibody for treating HER2-positive breast cancer. Although Alligator is not directly involved in the development, the company stands to benefit financially from potential future revenues due to its licensing agreement with AbClon, which entitles Alligator to a share of Henlius’ revenues from HLX22.
Alligator Bioscience AB has published a supplement prospectus related to its rights issue, which includes ordinary shares and warrants, approved by the Swedish Financial Supervisory Authority. The rights issue subscription period runs from December 4 to December 18, 2025, with trading in unit rights available until December 15, 2025. This move is part of the company’s strategy to secure additional subscription undertakings and guarantee commitments, potentially strengthening its financial position and supporting its ongoing drug development efforts.
Alligator Bioscience has released its financial calendar for 2026, detailing key dates for shareholders and stakeholders, including the submission deadline for resolutions, various interim and annual reports, and the Annual General Meeting. This announcement provides stakeholders with a clear timeline for the company’s financial disclosures and meetings, which is crucial for maintaining transparency and engagement with investors.
Alligator Bioscience AB has announced additional subscription undertakings and guarantee commitments for its upcoming rights issue, increasing the total commitments from approximately SEK 78 million to SEK 91 million. This financial support from both existing and new investors, including Roxette Photo SA, Magnus Petersson, and HDF Impact BV, strengthens the company’s ability to advance its mitazalimab treatment towards the market, highlighting investor confidence in Alligator Bioscience’s strategic direction.
Alligator Bioscience announced the publication of Phase 1 trial data for mitazalimab in Nature Communications, showcasing its potential in treating metastatic pancreatic ductal adenocarcinoma. The study demonstrated significant immunological effects, including reduced tumor fibrosis and increased T-cell infiltration, supporting mitazalimab’s role in reshaping the tumor microenvironment. These findings reinforce the drug’s potential in combination therapies for hard-to-treat cancers, aligning with Alligator’s broader clinical strategy.
Alligator Bioscience AB has announced a rights issue to raise approximately SEK 123 million, with the potential for an additional SEK 61 million through warrants. The funds will be used to repay loans and support the ongoing process to secure a partnership for mitazalimab, as well as for general corporate purposes. The rights issue is partially covered by subscription undertakings and guarantee commitments, ensuring a significant portion of the funds is secured.
Alligator Bioscience AB held an extraordinary general meeting on November 25, 2025, where several key resolutions were adopted. The company decided to amend its Articles of Association to adjust the limits for share capital and the number of shares, and to decrease its share capital to cover losses. Additionally, the meeting approved a rights issue of units, which is expected to raise approximately SEK 123 million before costs, and authorized the board to issue shares and warrants to guarantors and Fenja Capital II A/S as part of a loan restructuring. These measures aim to strengthen the company’s financial position and support its ongoing development efforts.
Alligator Bioscience AB has announced the final terms of its Rights Issue, which involves issuing units of ordinary shares and warrants to existing shareholders. The initiative aims to raise approximately SEK 123 million initially, with potential additional proceeds of SEK 61 million if warrants are fully exercised. The funds will be used to repay loans and support the company’s ongoing efforts to secure a partnership for its cancer treatment, mitazalimab, as well as for general corporate purposes. The Rights Issue is partially covered by subscription undertakings and guarantee commitments, ensuring a significant portion of the funds is secured.